• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Effects of probucol on atherosclerotic plaque and soluble thrombomodulin in patients with coronary heart disease
【2h】

Effects of probucol on atherosclerotic plaque and soluble thrombomodulin in patients with coronary heart disease

机译：普罗布考对冠心病患者动脉粥样硬化斑块和可溶性血栓调节蛋白的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study explored the effects of probucol on atherosclerotic plaques and soluble thrombomodulin in patients with coronary heart disease (CHD). Five hundred and eighty-three patients with CHD who were admitted to Jining First People's Hospital from February 2013 to February 2014. A total of 300 of them received conventional treatment, and were assigned to the control group, while the remaining 283 patients were treated with probucol in addition to the conventional treatment, and were assigned to the observation group. A retrospective analysis was performed on the total cholesterol levels, atherosclerotic plaque sizes, and soluble thrombomodulin levels. Probucol was administered at a dose of 500 mg twice a day for a period of 16 weeks. The total cholesterol level decreased gradually over time during the treatment. After 8 weeks of treatment, the total cholesterol level in the observation group was lower than that in the control group (P<0.05). After 8 weeks of treatment, the atherosclerotic plaque area in the observation group decreased compared with that before treatment (P<0.05). After 8 and 16 weeks of treatment, the plaque area in the observation group was smaller than that in the control group (P<0.05). The soluble thrombomodulin level at any time-point after treatment was lower than that before treatment in both groups (P<0.05). At the same time-point, the level in the observation group was lower than that in the control group (P<0.05). The total cholesterol and soluble thrombomodulin levels were positively correlated with the atherosclerotic plaque area (r=0.841, P=0.001; r=0.725, P=0.008). When patients with CHD were treated with probucol in addition to the conventional treatment, a reduction of the atherosclerotic plaque area, as well as a decrease of both the total cholesterol and soluble thrombomodulin levels, was observed. Overall, patients with CHD experienced improved symptoms following treatment with probucol.
机译：这项研究探讨了普罗布考对冠心病（CHD）患者的动脉粥样硬化斑块和可溶性血栓调节蛋白的影响。 2013年2月至2014年2月收治于济宁市第一人民医院的583例冠心病患者中，共有300例接受常规治疗，并划入对照组，其余283例接受了CHD治疗。普罗布考除常规治疗外，均分入观察组。对总胆固醇水平，动脉粥样硬化斑块大小和可溶性血栓调节蛋白水平进行回顾性分析。普罗布考以500 mg的剂量每天两次给药，持续16周。在治疗过程中，总胆固醇水平逐渐降低。治疗8周后，观察组总胆固醇水平低于对照组（P <0.05）。治疗8周后，观察组动脉粥样硬化斑块面积较治疗前减少（P <0.05）。治疗8、16周后，观察组斑块面积小于对照组（P <0.05）。两组治疗后任何时间点的可溶性血栓调节素水平均低于治疗前（P <0.05）。在同一时间点，观察组的水平低于对照组（P <0.05）。总胆固醇和可溶性血栓调节蛋白水平与动脉粥样硬化斑块面积呈正相关（r = 0.841，P = 0.001； r ​​= 0.725，P = 0.008）。当CHD患者除常规治疗外还接受普罗布考治疗时，发现动脉粥样硬化斑块面积减少，总胆固醇和可溶性血栓调节蛋白水平均下降。总体而言，冠心病患者在接受普罗布考治疗后症状得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号